Literature DB >> 15980150

Ras activity regulates cyclin E degradation by the Fbw7 pathway.

Alex C Minella1, Markus Welcker, Bruce E Clurman.   

Abstract

The Skp1-Cullin1 F-box protein-Fbw7 ubiquitin ligase regulates phosphorylation-dependent cyclin E degradation, and disruption of this pathway is associated with genetic instability and tumorigenesis. Fbw7 is a human tumor suppressor that is targeted for mutation in primary cancers. However, mechanisms other than mutation of Fbw7 may also disrupt cyclin E proteolysis in cancers. We show that oncogenic Ha-Ras activity regulates cyclin E degradation by the Fbw7 pathway. Activated Ras impairs Fbw7-driven cyclin E degradation, and, conversely, inhibition of normal Ras activity decreases cyclin E abundance. Moreover, activation of the mitogen-activated protein kinase pathway is the essential Ras function that inhibits cyclin E turnover, and activated Ha-Ras expression inhibits both the binding of cyclin E to Fbw7 and cyclin E ubiquitination. Last, we found that oncogenic Ras activity potentiates cyclin E-induced genetic instability but only when cyclin E is susceptible to degradation by Fbw7. Thus, we conclude that Ras activity regulates Fbw7-mediated cyclin E proteolysis and suggest that impaired cyclin E proteolysis is a mechanism through which Ras mutations promote tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15980150      PMCID: PMC1172263          DOI: 10.1073/pnas.0503677102

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  42 in total

1.  NPAT links cyclin E-Cdk2 to the regulation of replication-dependent histone gene transcription.

Authors:  J Zhao; B K Kennedy; B D Lawrence; D A Barbie; A G Matera; J A Fletcher; E Harlow
Journal:  Genes Dev       Date:  2000-09-15       Impact factor: 11.361

2.  Cyclin E ablation in the mouse.

Authors:  Yan Geng; Qunyan Yu; Ewa Sicinska; Manjusri Das; Jürgen E Schneider; Shoumo Bhattacharya; William M Rideout; Roderick T Bronson; Humphrey Gardner; Piotr Sicinski
Journal:  Cell       Date:  2003-08-22       Impact factor: 41.582

3.  Cell cycle-regulated phosphorylation of p220(NPAT) by cyclin E/Cdk2 in Cajal bodies promotes histone gene transcription.

Authors:  T Ma; B A Van Tine; Y Wei; M D Garrett; D Nelson; P D Adams; J Wang; J Qin; L T Chow; J W Harper
Journal:  Genes Dev       Date:  2000-09-15       Impact factor: 11.361

4.  Signals from Ras and Rho GTPases interact to regulate expression of p21Waf1/Cip1.

Authors:  M F Olson; H F Paterson; C J Marshall
Journal:  Nature       Date:  1998-07-16       Impact factor: 49.962

5.  Oncogenic potential of cyclin E in T-cell lymphomagenesis in transgenic mice: evidence for cooperation between cyclin E and Ras but not Myc.

Authors:  H Karsunky; C Geisen; T Schmidt; K Haas; B Zevnik; E Gau; T Möröy
Journal:  Oncogene       Date:  1999-12-16       Impact factor: 9.867

6.  Nucleophosmin/B23 is a target of CDK2/cyclin E in centrosome duplication.

Authors:  M Okuda; H F Horn; P Tarapore; Y Tokuyama; A G Smulian; P K Chan; E S Knudsen; I A Hofmann; J D Snyder; K E Bove; K Fukasawa
Journal:  Cell       Date:  2000-09-29       Impact factor: 41.582

7.  Induction of postmitotic neuroretina cell proliferation by distinct Ras downstream signaling pathways.

Authors:  C Peyssonnaux; S Provot; M P Felder-Schmittbuhl; G Calothy; A Eychène
Journal:  Mol Cell Biol       Date:  2000-10       Impact factor: 4.272

8.  Ras adenoviruses modulate cyclin E protein expression and DNA synthesis after partial hepatectomy.

Authors:  T Lüdde; S Kubicka; J Plümpe; C Liedtke; M P Manns; C Trautwein
Journal:  Oncogene       Date:  2001-08-30       Impact factor: 9.867

9.  Additive effects of tamoxifen and the farnesyl transferase inhibitor FTI-277 on inhibition of MCF-7 breast cancer cell-cycle progression.

Authors:  Sophie F Doisneau-Sixou; Philippe Cestac; Jean-Charles Faye; Gilles Favre; Robert L Sutherland
Journal:  Int J Cancer       Date:  2003-09-20       Impact factor: 7.396

Review 10.  Increasing complexity of Ras signaling.

Authors:  S L Campbell; R Khosravi-Far; K L Rossman; G J Clark; C J Der
Journal:  Oncogene       Date:  1998-09-17       Impact factor: 9.867

View more
  31 in total

1.  The repressing function of the oncoprotein BCL-3 requires CtBP, while its polyubiquitination and degradation involve the E3 ligase TBLR1.

Authors:  Aurore Keutgens; Kateryna Shostak; Pierre Close; Xin Zhang; Benoît Hennuy; Marie Aussems; Jean-Paul Chapelle; Patrick Viatour; André Gothot; Marianne Fillet; Alain Chariot
Journal:  Mol Cell Biol       Date:  2010-06-14       Impact factor: 4.272

Review 2.  The two faces of FBW7 in cancer drug resistance.

Authors:  Zhiwei Wang; Hidefumi Fukushima; Daming Gao; Hiroyuki Inuzuka; Lixin Wan; Alan W Lau; Pengda Liu; Wenyi Wei
Journal:  Bioessays       Date:  2011-08-30       Impact factor: 4.345

3.  Chromosome instability underlies hematopoietic stem cell dysfunction and lymphoid neoplasia associated with impaired Fbw7-mediated cyclin E regulation.

Authors:  Ka Tat Siu; Yanfei Xu; Kelsey L Swartz; Mitra Bhattacharyya; Sandeep Gurbuxani; Youjia Hua; Alex C Minella
Journal:  Mol Cell Biol       Date:  2014-06-23       Impact factor: 4.272

Review 4.  Prolyl isomerase Pin1 in cancer.

Authors:  Zhimin Lu; Tony Hunter
Journal:  Cell Res       Date:  2014-08-15       Impact factor: 25.617

5.  An integrated view of cyclin E function and regulation.

Authors:  Ka Tat Siu; Marsha Rich Rosner; Alex C Minella
Journal:  Cell Cycle       Date:  2012-01-01       Impact factor: 4.534

6.  Cyclin E controls Drosophila female germline stem cell maintenance independently of its role in proliferation by modulating responsiveness to niche signals.

Authors:  Elizabeth T Ables; Daniela Drummond-Barbosa
Journal:  Development       Date:  2013-02-01       Impact factor: 6.868

Review 7.  F-box proteins involved in cancer-associated drug resistance.

Authors:  Jian Gong; Yuqian Zhou; Deliang Liu; Jirong Huo
Journal:  Oncol Lett       Date:  2018-04-16       Impact factor: 2.967

Review 8.  p53: guardian of ploidy.

Authors:  Yael Aylon; Moshe Oren
Journal:  Mol Oncol       Date:  2011-07-30       Impact factor: 6.603

Review 9.  PIN1 in breast development and cancer: a clinical perspective.

Authors:  Alessandra Rustighi; Alessandro Zannini; Elena Campaner; Yari Ciani; Silvano Piazza; Giannino Del Sal
Journal:  Cell Death Differ       Date:  2016-11-11       Impact factor: 15.828

10.  Differences in degradation lead to asynchronous expression of cyclin E1 and cyclin E2 in cancer cells.

Authors:  C Elizabeth Caldon; C Marcelo Sergio; Robert L Sutherland; Elizabeth A Musgrove
Journal:  Cell Cycle       Date:  2013-01-16       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.